The onset of schizophrenia typically occurs during adolescence or early adulthood and is characterized by severe symptomatology and lifelong functional impairment. Cognitive dysfunction is common in schizophrenia and is associated with significant impairment in functioning. Very little is known about the long-term effects of antipsychotic treatment on cognition in adolescents with schizophrenia. To this extent, cognitive data are presented from an interim analysis of an ongoing 2-year long-term safety study of lurasidone in the treatment of children and adolescents with schizophrenia. Methods: Patients aged 13-17 years with schizophrenia who completed 6 weeks of double-blind (DB), placebo-controlled treatment with lurasidone were enrolled in a 2-year, open-label (OL) study in which patients were continued on lurasidone or switched from placebo to lurasidone. Cognitive function was assessed with the Brief CogState battery, which evaluates four cognitive domains: processing speed, attention/vigilance, visual learning, and working memory. Based on normative data, an overall cognitive composite Z-score was calculated as the average of the standardized Z-scores for each of the four cognitive domains. These results are based on an interim analysis of the 2-year data. Results: A total of 271 patients completed 6 weeks of double-blind treatment and entered the 2-year extension study. At the time of the interim analysis, 132 patients had completed 52 weeks of treatment (24 patients were 2-year study completers; 96 patients were still ongoing; and 12 patients had discontinued after 52 weeks); 57 patients were still ongoing in the first 1-year of treatment; and 82 patients terminated prior to week 52. The cognitive composite Z-score showed impairment at double-blind baseline (-1.09). Mean change in Z-score, from DB baseline to OL weeks 0 (OL-baseline), 28, 52, and 104, respectively, were observed for the cognitive composite (+0.04, +0.16, +0.30, +0.57), and for the CogState domains processing speed (-0.08, +0.02, +0.16, +0.68), attention/vigilance (0.00, 0.00, +0.05, +0.38), visual learning (+0.19, +0.45, +0.75, +1.07), working memory accuracy (+0.18, +0.24, +0.73, +0.30), working memory speed (+0.06, +0.23, +0.28, +0.15). Discussion: In this study of adolescents with schizophrenia, lurasidone was not associated with cognitive impairment after up to 104 weeks of treatment. Larger sample sizes are needed to confirm the robustness of the improvement was observed in selected cognitive domain scores, most notably visual learning and processing speed.
S74. EXPLORING PARTICIPANT-LEVEL TRAJECTORIES OF COGNITIVE PERFORMANCE AMONG PATIENTS WITH SCHIZOPHRENIA IN
Background: It remains unclear whether the lack of clinical trial success and drug approval for cognitive impairment associated with schizophrenia (CIAS) is due to compounds being ineffective, or whether trial methodology itself has been a limiting factor in successfully demonstrating the efficacy of these agents. Schizophrenia is a heterogeneous disorder and whilst cognitive deficits are a core feature, the profile and degree of neuropsychological impairment can vary across patients. Though most individuals with schizophrenia exhibit some general cognitive impairment compared to antecedent expectations, such as premorbid intelligence, up to a quarter display cognitive performance in the 'normal' range. This may pose a problem for pro-cognitive drug trials in this population given that it potentially inflates baseline scores and reduces the scope to see improvement between treatment and placebo groups. In order to examine this potential issue, we investigated participant-level trajectories of cognitive performance among patients with schizophrenia enrolled in a multi-national, phase II clinical trial. Methods: We conducted a post-hoc analysis of existing trial data from 463 patients with schizophrenia who participated in a randomized, double-blind, placebo-controlled trial. Patients met established diagnosis for schizophrenia (DSM-5), were clinically stable (non-acute) and had no more than moderate severity ratings on the Positive and Negative Syndrome Scale (PANSS). During the trial, participants completed two different neurocognitive test batteries, the Cambridge Neuropsychological Test Automated Battery (CANTAB) and the MATRICS Consensus Cognitive Battery (MCCB), at 4 separate time points (screening, baseline, week 6 & week 12). Participant data were pooled across placebo and treatment groups to explore trajectories of cognitive performance, at the participantlevel, across the course of the study. Results: Linear mixed model analyses revealed that participants who performed within the 'normal range' at screening on cognitive tasks as measured by CANTAB, continued to perform well at baseline, week 6 and week 12, showing no significant change in their performance. By contrast, participants who performed below the normal range at screening, showed a significant improvement in their test performance across the remainder of the study. When compared in the context of MCCB, those participants who performed a standard deviation (SD) above the MCCB normative mean at screening, were also the participants who performed within the normal range on CANTAB. Approximately 25% of the overall sample were performing within a clinically normal cognitive range at screening. Discussion: Substantial variability was evident in cognitive performance among the current sample of patients with schizophrenia. We identified a subsample of patients whose performance fell within a clinically normal range. Cognitive improvement was observed only in those who exhibited a deficit at screening, bringing into question whether the inclusion of unimpaired patients in clinical trials increases the risk of ceiling effects and minimizes chance to see change. Further analyses will determine the interaction between different cognitive trajectories and the treatment arms included in this trial to explore whether there are individuals with a particular cognitive profile who are most likely to respond to treatment. This has potentially important methodological implications in the search to find a drug to treat CIAS. 
S75. MALADAPTIVE SOCIAL-EVALUATIVE AND SELF-BELIEFS INFORMING THE RELATION

University of Maryland School of Medicine
Background: Paranoid delusions are reported among those with positive symptoms of schizophrenia (Bentall et al., 2009 ), those at high-risk for the development of psychosis (Addington et al., 2015; Salokangas et al., 2016) , and in the general population (i.e., Freeman et al., 2005) . Paranoia is related to functional impairment in multiple domains (i.e. Pinkham et al., 2016; McGurk et al., 2013) . Given the presence of paranoia at both clinical and non-clinical levels, paranoia may be best conceptualized dimensionally. Further, robust relations between paranoia and social anxiety suggest that the two may exist together on one spectrum, with paranoia reflecting the most extreme end of this continuum (i. Evidence suggests that several factors may influence the development of paranoia, including social cognitive biases such as diminished trust, increased hostility, and increased tendency to blame others (Pinkham et al., 2014) . These types of social cognitive biases do not seem to be unique to paranoia and are also observed among those with social anxiety (i.e., Green & Phillips, 2004) . Additional research suggests that paranoia and social anxiety may share other relevant attributes, such as need for approval from others (Rector, 2004) , desire for closeness (Lim, Rodebaugh, Zyphur & Gleeson, 2016) , and worry about and expectation of social rejection (Freeman, 2014) . Despite literature to support overlap between paranoia and social anxiety, there is less research examining whether core beliefs of social anxiety contribute to the development and maintenance of paranoia. Specifically, core beliefs of social anxiety include (1) conditional beliefs: negative self-appraisals dependent on performance (2) unconditional beliefs: negative self-appraisals independent of behavior, and (3) high-standard beliefs: the attribution of self-worth based on performance (Wong, Moulds & Rapee, 2014) . There is a need for research to determine the association between paranoia and beliefs related to social anxiety. The aim of the current study is to identify whether cognitions thought to be central to social anxiety are also related to paranoia in a sample of those with psychosis. We hypothesize that (1) social anxiety and paranoia will be related, and (2) heightened maladaptive self-beliefs of social anxiety will be associated with increased paranoia. Methods: We will use the Social Interaction Anxiety Scale (Heimberg, Mueller, Holt, Hope & Liebowitz, 1992) to measure social anxiety symptomatology. We will use the Self-Beliefs Related to Social Anxiety Scale (Wong, Moulds & Rapee, 2014) including three subscales: conditional beliefs, unconditional beliefs, and high standard beliefs, to quantify cognitions of social anxiety. To measure paranoia, we will use the Green Paranoid Thoughts Scale (Green et al., 2008) . Results: Preliminary analyses (N = 14) indicate that the social anxiety is robustly related to paranoia (r = 0.59, p < 0.05). Unconditional beliefs were related to paranoid thoughts (r = 0.62, p < 0.05) and paranoia was moderately correlated to conditional beliefs (r = 0.35, p = 0.24) and total self-beliefs related to social anxiety scores (r = 0.39, p = 0.19), but these relations were not statistically significant. Additional data will be available at the time of presentation. Discussion: Results of this research will both inform the development of paranoia and allow for a better understanding of the relation between paranoia and social anxiety. Specifically, cognitive mechanisms underlying their relation will be illuminated. 
S76. A BEHAVIOURAL ECONOMIC ANALYSIS OF EFFORT-RELATED CHOICE IN SCHIZOPHRENIA
University of Toronto
Background: Motivational deficits are prevalent feature of schizophrenia, which have been tightly linked to real-world outcomes. Abnormalities in effort cost computations have been proposed as a candidate mechanism underlying these deficits. In the present study, we sought to employ behavioural economic analyses to further understand cost-benefit decision making abnormalities in schizophrenia. Methods: 58 young adults with schizophrenia and 58 matched controls participated in this study. Participants completed an effort-based decision-making task in which they made decisions to expend physical effort in exchange for monetary rewards. From participants choice behaviour, we computed indifference values (i.e. the reward value at which participants would be indifferent to expending effort vs not) for each individual participant. Other computational parameters were also computed such as choice consistency and subjective reward valuation. Results: Patents and controls did not differ in their subjective valuation of reward. On the decision-making task, patients made more inconsistent choices relative to controls. In both univariate and multivariate analyses controlling for potential confounders, patients had higher indifference values meaning that patients required more money in the exchange of their effort. Among patients, higher indifference values were associated with more severe clinical motivational deficits. Discussion: Patients had multiple abnormalities related to their decisions to expend effort for reward. Choices were more chaotic and reward value was discounted by effort at a steeper rate in patients. These results point toward an abnormality in the computation of effort costs or in the integration of these costs with value signals.
S77. JUMPING TO CONCLUSIONS AND FACIAL EMOTION RECOGNITION IMPAIRMENT IN FIRST EPISODE PSYCHOSIS ACROSS EUROPE
